| Dec 31,
2019 | Dec 31,
2020 | Dec 31,
2021 | Dec 31,
2022 | Dec 31,
2023 | Dec 31,
2024 |
|---|
| Net loss | -105 | -190 | -36 | -133 | -130 | -119 |
|---|
| Depreciation and amortization | 4 | 6 | 6 | 6 | 6 | 5 |
|---|
| Stock-based compensation | 16 | 31 | 41 | 46 | 43 | 39 |
|---|
| Amortization of premiums and accretion of discounts on marketable securities | 5 | -1 | -2 | 1 | 15 | 14 |
|---|
| Amortization Right Of Use Asset | 2 | 1 | 2 | 3 | 3 | 3 |
|---|
| Operating Lease, Impairment Loss | 1 | 0 | - | - | - | 2 |
|---|
| Loss from disposal of fixed assets | - | - | - | - | -0 | - |
|---|
| Receivable from collaboration partner | - | - | 7 | -5 | -3 | - |
|---|
| Prepaid expenses and other current assets | 2 | 4 | -1 | 4 | 6 | -6 |
|---|
| Other assets | 0 | 2 | 3 | 1 | 1 | -3 |
|---|
| Accounts payable | 0 | 2 | 2 | -1 | -0 | -1 |
|---|
| Accrued liabilities and accrued clinical supply costs | 9 | 12 | 2 | -3 | 3 | 0 |
|---|
| Payable to collaboration partner | - | - | - | - | 8 | -2 |
|---|
| Deferred revenue | -21 | -21 | 293 | 66 | -67 | -101 |
|---|
| Refund liability to collaboration partner | - | - | - | - | 25 | 46 |
|---|
| Lease liabilities | 1 | -2 | -4 | -4 | -5 | -6 |
|---|
| Other long-term liabilities | 0 | -0 | -0 | 1 | 1 | -0 |
|---|
| Net cash used in operating activities | -99 | -167 | 299 | -20 | -184 | -230 |
|---|
| Purchase of property and equipment | 15 | 5 | 3 | 4 | 2 | 1 |
|---|
| Purchase of marketable securities | 530 | 507 | 343 | 557 | 552 | 468 |
|---|
| Maturities of marketable securities | 496 | 407 | 286 | 402 | 653 | 574 |
|---|
| Sale of marketable securities | - | - | 11 | - | 4 | 3 |
|---|
| Net cash provided by (used in) investing activities | -49 | -105 | -50 | -159 | 102 | 107 |
|---|
| Proceeds from Stock Options Exercised | 2 | 6 | 29 | 3 | 1 | - |
|---|
| Proceeds from Stock Plans | 1 | 1 | 2 | 1 | 1 | 1 |
|---|
| Proceeds from Issuance of Common Stock Upon Public Offering Net of Issuance Costs | - | - | - | - | - | 71 |
|---|
| Proceeds from debt financing, net of discount and issuance costs | - | - | - | - | - | 9 |
|---|
| Net cash provided by financing activities | 172 | 232 | 30 | 5 | 3 | 82 |
|---|
| Net decrease in cash, cash equivalents, and restricted cash | 24 | -40 | 279 | -175 | -80 | -41 |
|---|
| Capital Expenditures Incurred but Not yet Paid | 3 | 0 | 1 | 0 | 0 | - |
|---|